WO2004087110A1 - 分割錠 - Google Patents
分割錠 Download PDFInfo
- Publication number
- WO2004087110A1 WO2004087110A1 PCT/JP2004/004369 JP2004004369W WO2004087110A1 WO 2004087110 A1 WO2004087110 A1 WO 2004087110A1 JP 2004004369 W JP2004004369 W JP 2004004369W WO 2004087110 A1 WO2004087110 A1 WO 2004087110A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet
- center
- divided
- line
- angle
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract description 15
- 230000008961 swelling Effects 0.000 abstract 1
- 239000003826 tablet Substances 0.000 description 214
- 238000003860 storage Methods 0.000 description 21
- 238000003825 pressing Methods 0.000 description 17
- 238000010586 diagram Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 5
- 229920002678 cellulose Polymers 0.000 description 5
- 235000010980 cellulose Nutrition 0.000 description 5
- -1 chemotherapeutics Substances 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000004088 foaming agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 229960000913 crospovidone Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000012778 molding material Substances 0.000 description 2
- 239000007935 oral tablet Substances 0.000 description 2
- 229940096978 oral tablet Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241001391944 Commicarpus scandens Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000003905 agrochemical Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WLDHEUZGFKACJH-UHFFFAOYSA-K amaranth Chemical compound [Na+].[Na+].[Na+].C12=CC=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(O)=C1N=NC1=CC=C(S([O-])(=O)=O)C2=CC=CC=C12 WLDHEUZGFKACJH-UHFFFAOYSA-K 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007936 buccal or sublingual tablet Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
- 229960005132 cisapride Drugs 0.000 description 1
- DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 1
- 229960005452 cobamamide Drugs 0.000 description 1
- 235000006279 cobamamide Nutrition 0.000 description 1
- 239000011789 cobamamide Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- JFVXEJADITYJHK-UHFFFAOYSA-L disodium 2-(3-hydroxy-5-sulfonato-1H-indol-2-yl)-3-oxoindole-5-sulfonate Chemical compound [Na+].[Na+].Oc1c([nH]c2ccc(cc12)S([O-])(=O)=O)C1=Nc2ccc(cc2C1=O)S([O-])(=O)=O JFVXEJADITYJHK-UHFFFAOYSA-L 0.000 description 1
- PVBRXXAAPNGWGE-LGVAUZIVSA-L disodium 5'-guanylate Chemical compound [Na+].[Na+].C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP([O-])([O-])=O)[C@@H](O)[C@H]1O PVBRXXAAPNGWGE-LGVAUZIVSA-L 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 235000013896 disodium guanylate Nutrition 0.000 description 1
- 239000007947 dispensing tablet Substances 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000000887 face Anatomy 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229960002600 icosapent ethyl Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960004114 olopatadine Drugs 0.000 description 1
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229950001089 todralazine Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Definitions
- the present invention relates to a divided tablet.
- Divided tablets are tablets that are divided by the pharmacist at the time of dispensing according to the dose, or by the patient at the time of taking, which optimizes dose management for individual patients and improves the convenience of prescription Is being developed for
- Such a divided tablet is generally provided with a dividing line (a dividing groove) for dividing the tablet.
- Examples of divided tablets include, for example, Japanese Utility Model Application Laid-Open No. 8-11012, Japanese Utility Model Application Model No. 7_193339, Japanese Patent Application Laid-Open No. H8-2777217, U.S. Pat. 8 2 4 6 7 7
- the dividing operation may be either a method in which a pharmacist or patient grasps the disintegrant with both hands to open (or close) the score line, or a rigid device such as a desk. On a flat surface, a method is used in which the back side is pressed along the score line or just behind the score line with the edge of a subhum or the like.
- Japanese Utility Model Publication No. 40-3680, Patent No. 3015677, and British Patent No. 1387643 WO 99/51207 have made it possible to easily divide a tablet by holding a divided tablet between two flat plates. It is also possible to divide the score by pressing the finger down with the score line facing down on a flat surface. Furthermore, even from above the packaging such as PTP, division is possible if the secant line points downward. In these split tablets, if the split tablet is sandwiched between two flat boards, the point of contact between the split tablet and the flat surface will be located one place on both sides of the split line, and on the other side of the split line, after the split line. It is located at one point on the back side, and it has three points of emphasis that can be divided.
- the surface extending from the above-mentioned contact point to the bottom of the split line has an upwardly convex surface even when the split line is upwardly pressed on a flat surface and pressed from above.
- the surface of the finger or PTP container forms a new appropriate contact point, and the other side of the score line comes into contact with a flat surface just behind the score line, creating three points of force, allowing division It has become.
- the split tablet of Japanese Utility Model Publication No. 40-3680, Patent No. 3015677, and British Patent No. 187643 is difficult to properly contact both sides of the split line when the split line is turned upward and pressed from above, and it is difficult to crack.
- splitting can be easily performed by holding the split tablet between two flat boards and pressing it, and it can also be split easily by pressing the split line downward on a flat surface and pressing with a finger from above.
- a splittable tablet that can be easily divided by such a method and has a high tableting strength in addition to a sharp division and a high divisional accuracy has not been specifically disclosed so far. Also, despite the keen demand for disclosure of such technology, it has been difficult to clarify the fact that the shape of the divided tablet is a unique polyhedron, which is difficult. Disclosure of the invention
- the purpose of the present invention is to divide the tablet by holding the divided tablet between two flat plates It is also possible to divide by dividing the score line downward on a flat surface and pressing it with a finger, etc. It is an object of the present invention to provide a divided tablet which can be divided easily regardless of whether the upper surface or the lower surface is facing upward, and which can be easily and accurately divided, and which has excellent strength.
- the present inventors have conducted intensive studies in order to achieve the above object, and as a result, by determining not only the angle of the dividing line but also the entire shape as described below, the divided tablet is sandwiched between two flat plates and pressed. It is possible to divide by dividing the dividing line by pressing the finger down on a flat surface with the dividing line facing down, and it is possible to divide even from the top of the packaging such as PTP by the same method. It has been found that a dividable tablet is preferably a dividable tablet that can be divided regardless of whether the upper or lower surface of the tablet is facing upward, and that a dividable tablet that can be easily and accurately divided and has excellent strength can be obtained. did. The present inventors have further studied and completed the present invention.
- the lower surface is a curved surface that gradually rises from the center immediately below the 3 ⁇ 41 line, and the upper surface is divided by at least one U-shaped groove or V-shaped groove with a central angle of 105 ° or less.
- each of the center of the lower surface and the two or more upper surfaces farthest from the tangent to the center of the lower surface
- the angle at the center of the lower surface is 70 ° or more, and any one of the two or more upper surfaces furthest from the tangent at the center of the lower surface
- the ratio cZd of the distance (c) from the center of the lower surface to the tangent at the center and the distance (d) from the lowermost part of the secant line to the center of the lower surface is 0.70 ⁇ c / d ⁇ 1 / 40.40.
- the lower surface is a curved surface that gradually rises from the center just below the score line, and the upper surface is divided into two or more by a score line consisting of at least one U-shaped groove or V-shaped groove with a central angle of 105 ° or less.
- a divided tablet having a ridge line that is divided into surfaces and is provided in each of a plurality of regions formed by the score line so as to surround the score line and to be located inside the edge of the tablet.
- the angle at the center of the lower surface is at least 70 °, and the distance between each of the two or more upper surfaces farthest from the tangent at the center of the lower surface and the tangent at the center of the lower surface (c) And the ratio (d) of the distance (d) between the bottom of the secant and the center of the lower surface is 1Z0.
- FIG. 1 is a schematic diagram showing a specific embodiment of the divided tablet of the present invention.
- A1 is a schematic diagram viewed from the top
- B1 is a schematic diagram of a side surface viewed from an extension of the score line.
- FIG. 2 is a schematic view showing another specific embodiment of the divided tablet of the present invention.
- A2 is a schematic diagram viewed from the top
- B2 is a schematic diagram of a side surface viewed from an extension of the score line.
- FIG. 3 is a side view schematically showing a phenomenon that occurs in the divided tablet when the divided tablet of the present invention is divided by sandwiching and holding the divided tablet of the present invention between two flat plates.
- FIG. 4 shows the split tablet (40) of the present invention, which is stored in the storage recess (41) of the storage body of the PTP with the sealing sheet (42) facing the upper surface provided with the score line.
- FIG. 4 is a side view schematically showing a phenomenon that occurs in the divided tablet when the divided tablet of the present invention is divided by applying a vertical force from above to below before taking out the divided tablet of the present invention from the storage recess.
- FIG. 5 shows the split lock (40) according to the present invention, which is stored in the storage recess (41) of the storage body of the PTP with the upper surface provided with the dividing line facing the storage body (43).
- FIG. 5 is a side view schematically showing a phenomenon that occurs in the divided tablet when the divided tablet of the present invention is divided by applying a vertical force from above to below before taking out the divided tablet of the present invention from the storage recess.
- FIG. 6 is a schematic diagram schematically showing the shape of the score line provided in the divided tablet according to the present invention.
- reference numeral 1 denotes a lower surface
- reference numeral 2 denotes a dividing line
- reference numeral 3 denotes a central portion (center)
- reference numeral 6 denotes a tangent of the lower surface 1 at the center 3
- reference numerals 7 and 8 denote tangents 6 of the lower surface 1 to the center 3.
- the points on the upper surface furthest from are indicated by the symbols 9 and 10 at the ridgeline, the symbols 12 and 13 are at the start of the secant line 2, the symbol is the radius of curvature of the lower surface 1, and the symbol a is the center of the secant line 2.
- the angle, symbol is the angle at the center 3 of the lower surface 1 of the temporary triangle connecting the center 3 of the lower surface 1 and points 7 and 8, respectively, and the symbol c is the center of either the point 7 or 8 and the lower surface 1.
- Distance from tangent 6 to 3 The symbol is the distance between the bottom line 1 1 of the dividing line 2 and the center 3 of the lower surface 1, the symbol 18 is the lower surface, the symbol 19 is the dividing line, the symbol 20 is the center (center), the symbol 2 3 is the tangent of the center 20 of the lower surface 18, reference numerals 24 and 25 are the points of the upper surface furthest from the tangent 23 of the center 20 of the lower surface 18, and reference numerals 26 and 27 are the ridge, code 2 9, 3 0 the starting end of the dividing line 1 9, reference numeral R 2 is a radius of curvature of the lower surface 1 8, the curvature radius of the letter S 2 designates a top surface, reference numeral a 2 is the central angle of the dividing line 1 9
- reference numeral 40 denotes a divided lock
- reference numeral 41 denotes a storage recess
- reference numeral 42 denotes a sealing sheet
- reference numeral (a) denotes V
- the symbol (b) represents a V-shaped groove shape having a round round shape near the apex angle
- the symbol (c) represents a V-shaped groove shape having at least one bent portion near the apex angle.
- the divided tablet according to the present invention includes a split tablet having two or more score lines.
- a divided tablet with one score line will be described as an example.
- the split tablet of the present invention has a curved surface whose lower surface is gradually raised with the center right below the score line, and whose upper surface is formed by at least one U-shaped groove or a V-shaped groove having a central angle of 105 ° or less.
- points on the upper surface furthest from the tangent at the center of the lower surface are at least on each side of the dividing line.
- the divided tablet of the present invention preferably has the following aspects.
- the split tablet of the present invention has a curved surface whose lower surface is gradually raised from the central portion immediately below the score line, and whose upper surface is formed of at least one U-shaped groove or a V-shaped groove having a central angle of 105 ° or less.
- the tablet is divided into two or more surfaces, and a ridge line is provided in each of a plurality of regions formed by the score lines so as to surround the score lines, as shown in FIG.
- a ridge line is provided in each of a plurality of regions formed by the score lines so as to surround the score lines, as shown in FIG.
- the upper surface of the split tablet touches the flat surface at at least one location on both sides of the split line (7 and 8 in Fig. 3).
- the lower surface of the split tablet touches the flat surface at the center (3 in Fig.
- the distance between points 7 and 3 is usually the same as the distance between points 8 and 3.
- a divided tablet (40 in Fig. 4) is housed with the sealing sheet (42 in Fig. 4) facing the upper side with the dividing line facing it.
- the tablet can be easily divided into two by pressing the convex central portion of the lower surface of the tablet with a finger from above the storage recess of the PTP storage body.
- the center on the lower surface may be a surface, a line, or a point.
- the upper surface is divided into two surfaces by a dividing line consisting of one U-shaped groove or a V-shaped groove having a central angle of 105 ° or less, and each of the two regions formed by the dividing line
- a divided tablet is provided with a ridge so as to surround the dividing line and to be located inside the edge of the tablet.
- the peripheral region of the ridge line is formed of a convex curved surface.
- the peripheral area of the ridge line is chamfered.
- the shape of the surface from the line that is the starting point of the score line to the ridge line is configured by a convex curved surface.
- the upper surface is divided into two surfaces by a dividing line composed of one U-shaped groove or a V-shaped groove having a central angle of 105 ° or less, and the upper surface is divided into two regions formed by the dividing lines.
- a ridge line is provided so as to surround the score line and to be located inside the edge of the tablet, and each of the two lines formed by the score line on the upper surface of the tablet is a starting line of the score line.
- the shape of the surface from to each of the two ridgelines is composed of a convex curved surface.
- the “convex surface” is a gentle raised surface. More specifically, as a whole, the curvature gradually changes from the surface having the small curvature to the surface having the large curvature in the direction of the ridge line from the line that is the start of the secant line. Case where the surface has a raised surface. More preferably, the “convex-shaped curved surface” is a curved surface having a radius of curvature larger than about 4 mm. Since the divided tablet of the present invention has the above-described shape, as shown in FIG.
- the divided tablet is stored in the storage recess of the PTP storage main body with the sealing sheet facing the upper surface provided with the score line.
- the PTP storage recess (41 in Fig. 5) with the dividing line provided on the top is the storage body (43 in Fig. 5). Even if the split tablet is stored so as to face the PTP, the PTP storage recess (Fig. 5 By pressing with a finger from above 4 1), the split tablet can be easily split into two. As shown in FIG. 5, when the division of the divided tablet is viewed from the side, two areas formed by the dividing line on the upper surface of the tablet along the shape of the storage recess or the finger that is crushed in a substantially V shape.
- the tablet Since each has a curved surface facing each other, the force acts in the direction of opening the secant line without applying great force to the finger. Thus, even if the tablet is stored in the storage recess of the PTP such that the upper surface provided with the dividing line of the tablet faces the storage body, the tablet can be more easily divided into two. As described above, in the divided tablet according to the present embodiment, even when the tablet is stored in the storage recess of the storage body of the PTP without restricting the direction, the tablet can be easily split into two before taking out the tablet from the PTP. It has the advantage of being able to.
- the divided tablet of this embodiment has two convex surfaces on the upper surface and a convex surface on the lower surface, the tablets do not make surface contact with each other but make point contact. As a result, there is an advantage that twinning is unlikely to occur in the coating process. Furthermore, the divided tablet of the present invention can be easily divided by taking out the tablet from the PTP and pressing the score with a finger or the like regardless of whether the score is placed on a flat surface either downward or upward. .
- the point of emphasis may deviate from the point on the upper surface farthest from the tangent at the center of the lower surface.
- the surface from the contact point to the bottom of the secant line has a convex upward shape, the surface and the finger newly form an appropriate contact point. Since it touches a flat surface at the center, three points of force are generated and division is possible.
- another aspect of the tablet that can be divided regardless of whether the upper surface or the lower surface of the divided tablet is facing upward is a dividing line starting from each of two points on the upper surface furthest from the tangent at the center of the lower surface.
- Divided tablets whose straight line forms an angle of about 30 ° or less with the tangent at the center of the lower surface.
- the line from the ridge line to the secant line may be a straight line, a concave-shaped curve, or a wavy curve.
- the dividing line provided on the upper surface has a V-shaped groove. Or u-shaped groove.
- the central angle of the V-shaped groove is 105 ° or less, preferably 90 ° or less, more preferably 70 ° or less.
- the “V-shaped groove” includes a case where the groove is substantially a V-shaped groove.
- the “generally V-shaped groove” is, for example, a shape in which the vicinity of the apex angle of the V-shaped groove is formed as a round curve, or a shape such as around a vertex of a parabola (quadratic curve), or The case where the vicinity of the apex angle of the V-shaped groove is a polygonal shape having a bent portion is included. More specifically, even though the V-shaped groove in the present invention has a V-shaped groove shape as shown in FIG.
- the groove may be a V-shaped groove having a shape having a vertical axis, or a V-shaped groove having a polygonal shape having one or more bent portions 62 near the apex angle as shown in FIG. 6 (c).
- the U-shaped groove includes a case where the U-shaped groove is substantially a U-shaped groove.
- the “generally U-shaped groove” includes, for example, a case where a round curved portion of the U-shaped groove is formed into a polygonal shape having a bent portion. More specifically, the U-shaped groove in the present invention may have a U-shaped groove shape as shown in FIG. 6 (d), or a smooth curve (see FIG. 6 (e)) at the lower part. Instead of the region 63) shown in FIG. 6 (d), a U-shaped groove having one or more bent portions 62 may be used. As shown in Fig.
- the V-shaped groove includes a V-shaped groove in which convex curves intersect, there is no inflection point at the end of the dividing line, and the end of the dividing line and the ridge line Including the case where they are the same.
- the center of the lower surface and the two or more points of the upper surface furthest from the tangent to the center of the lower surface at each point in a temporary triangle connecting any two points (hereinafter simply referred to as a “temporary triangle”), the angle at the center of the lower surface is preferably about 70 ° or more, more preferably about 75 ° or more, 78 ° or more is more preferable.
- the surface from the ridge line on the upper surface to the center line of the dividing line should be a curved surface.
- the surface bend at the start of the score line in order to make it easier and more accurate to divide the divided tablet of the present invention, one of each of two or more upper surfaces furthest from the tangent at the center of the lower surface and the center of the lower surface are used.
- the ratio cZd of the distance (c) from the tangent to the distance (d) between the bottom of the secant and the center of the lower surface is preferably in the following range in relation to the angle at the center of the lower surface of the temporary triangle. .
- the ratio cZd is more preferably set to about 1Z0.60 ⁇ c / d ⁇ l / 0.40.
- the ratio cZd is more preferably set to about 10.6 ⁇ c / ⁇ l / 0.40.
- the ratio cZd is more preferably set to about 1Z0.70 ⁇ c / 6 ⁇ l / 0.40. Further, it is more preferable that the ratio cZd be about 1 / 0.60 ⁇ c / d ⁇ 1 / 0.50 regardless of the angle at the center of the lower surface of the temporary triangle.
- the ratio c / d is 1 / 0.60 ⁇ c / d ⁇ 1 / 0.50, it is more preferable that the angle at the center of the lower surface of the temporary triangle be 78 ° C or more.
- the contour when viewed from the top surface can be any shape such as a circle, an ellipse, a polygon or a star, but a circle or an ellipse is preferred. Tablets can be large or small, for example, about 6 to 12 mm in diameter, or about 3 to 6 mm in diameter for smaller ones. Degree.
- the thickness with respect to the diameter of the tablet (the value in FIG. 1 and the c 2 value in FIG. 2) is 0.25 or more with respect to the diameter 1 in order to improve the opportunity strength of the whole tablet. And more preferably 0.40 or more.
- the lower surface of the split tablet of the present invention has a curved surface having a radius of curvature larger than 7 mm, and a radius of curvature of 9 mm. It is more preferable to have a larger curved surface, and it is most preferable that the curved surface has a radius of curvature larger than 11 mm.
- the divided tablet of the present invention preferably further has any one of the shapes described in the following (a) to (d).
- the distance between the lowermost part of the score and the center of the lower surface is shorter than the distance between the point on the upper end of the tablet edge and the tangent of the center of the lower surface.
- the dividing line of the tablet is formed deeper than the dividing line of the ordinary divided tablet, so that the tablet can be divided clearly along the dividing line.
- each of the lines starting from the score be provided at a position above the upper end of the tablet ⁇ . That is, it is preferable that the distance between the point on the line serving as the starting point of the score line and the tangent at the center of the lower surface is longer than the distance between the point on the upper end of the tablet edge and the tangent at the center of the lower surface.
- a score line is formed deep from the upper surface of the tablet in the longitudinal direction of the tablet, and if the depth of the score line is increased, it becomes easier to split into two, but the mechanical strength in the area where the score line is provided
- the tablet is easily divided into two, even though it is not intended to be divided.
- the depth of the score line can be increased without significantly lowering the mechanical strength of the tablet in the area where the score line is provided, so that the tablet can be easily divided into two.
- the tablet will be split into two if not intended to be split Is virtually eliminated.
- the shape from the plurality of, preferably two, ridges on the upper surface of the tablet to the upper end of the tablet edge is preferably a steep slope.
- the “steep slope” is preferably a straight or convex curve in a side view of the tablet viewed from an extension of the dividing line of the divided tablet. Whether the shape of the “steep slope” is a straight line or a convex curved line may be determined from the design aspect of the tablet. That is, the shape of the tablet can be produced based on the medicinal effect, efficacy, effect, etc. of the divided tablet so that the doctor can impress the shape of the tablet to a doctor, pharmacist, patient, or the like.
- the score line is chamfered in a region near a portion intersecting with a part of the tablet. Further, it is more preferable that the neighboring area is chamfered into two convex shapes formed so as to sandwich the dividing line. With such a structure, the tablet is less likely to be chipped.
- FIG. 1 shows a specific embodiment of the present invention.
- A1 is a schematic diagram viewed from the top
- B1 is a schematic diagram of a side surface viewed from an extension of the dividing line.
- the lower surface 1 is a curved surface that gradually rises with the center 3 immediately below the score line 2.
- the “center of the lower surface” is a point, and indicates the same point as the “center of the lower surface”.
- the “center of the lower surface” may be not only a point but also a line or a surface.
- the upper surface is divided by dividing lines 2 into surfaces 4 and 5, and surfaces 4 and 5 have ridge lines 9 and 10 across the dividing line. From the tangent 6 of the center 3 of the lower surface 1 to the most ⁇ S Points 7 and 8 on the far top are on ridges 9 and 10, one on each side of secant 2 (sides 4 and 5). From the ridge lines 9 and 10 to the lowermost line 11 of the secant line 2, it consists of two surfaces 14 and 15 and surfaces 16 and 17 that are inflected by lines 12 and 13, respectively.
- the radius of curvature of the lower surface 1 is denoted by, the central angle of the secant line 2 is denoted by a, and the center 3 of the lower surface 1 is connected to the points 7 and 8 on the surfaces 4 and 5, respectively.
- the angle at the center 3 of b is indicated by b
- the distance between one of points 7 and 8 and the tangent 6 of the center 3 of the lower surface 1 is indicated by c
- 1 ⁇ is preferably about 9 mm or more, more preferably about 9 mm or more, most preferably about 1 lmm or more
- ai is preferably about 105 ° or less, and about 90 ° or less.
- the ratio c 1 7 (1 1 c and di is preferably 1 0. 70 ⁇ c 40 about der Rukoto.
- the point ⁇ the tangent The distance to 6 is usually the same as the distance between point 8 and tangent 6.
- FIG. 2 shows a specific embodiment in which the divided tablet of the present invention is a tablet that can be divided regardless of which of the upper and lower surfaces faces upward.
- A2 is a schematic diagram viewed from the top
- B2 is a schematic diagram of a side surface viewed from an extension of the dividing line.
- the lower surface 18 is a curved surface that gradually rises with the central portion 20 right below the dividing line 19.
- the “center of the lower surface” is a point, and indicates the same point as the “center of the lower surface”.
- the upper surface is divided into surfaces 21 and 22 by a V-shaped groove 19, and the surfaces 21 and 22 have ridge lines 26 and 27 across the dividing line.
- Lower surface 18 center 20 tangent Points 24 and 25 on the top surface furthest from 23 are on both sides of secant line 19 (surfaces 21 and
- the curvature radius of the lower surface 18 indicated as R 2, the radius of curvature of the surface 31 and 33 shows the S 2 represents the center angle of the dividing line 19 and a 2, the center 20 of the lower surface 18, surface 21 and upper 22 the angle that put the center 20 of the lower surface 18 triangular temporary connecting each of the points 24 and 25 of b 2 and shows the distance between any of the points 24 and 25 and tangential 2 3 of the center 20 of the lower surface 18 c 2 shows, when the g ⁇ the center 20 the lower surface and bottom line 28 of the dividing line 19 shown as d 2,; 2 is about the more preferably at least preferably fixture about 9mm or 7 mm, about 11mm or more S 2 is preferably about 4 mm or more, a 2 is preferably about 105 ° or less, more preferably about 90 ° or less, most preferably about 70 ° or less, and b 2 is about 70 ° or more.
- the ratio c 2 Zd 2 of c 2 and d 2 is 1Z0. 60 ⁇ c 2 / d 2 ⁇ l / 0. 40 mm, also b 2 If there is less than 75 ° or 78 °, the ratio c 2 Zd 2 of c 2 and d 2 is 1Z0. 65 ⁇ c 2 / d 2 ⁇ 1/0. about 40, also if b 2 is equal to or greater than 78 °, the ratio c 2 Zd 2 of c 2 and d 2 is 1/0. 70 ⁇ c 2 / d in 2 ⁇ 1/0. 40 about Preferably, there is.
- the distance between point 24 and tangent 23 is usually the same as the distance between point 25 and tangent 23.
- the divided tablet of the present invention only needs to have the above-mentioned shape, and there is no limitation on the contained components.
- the active ingredients that can be contained in the divided tablet of the present invention include, for example, drugs for the central nervous system, drugs for the peripheral nervous system, drugs for the circulatory organ, drugs for the digestive tract, hormones, drugs for the urogenital organs, blood
- active ingredients selected from body fluids, metabolic drugs, drugs for oncology, drugs for allergies, antibiotics, chemotherapeutics, vitamins, diagnostics, narcotics and stimulants, and the like.
- acetylsviramisin amoxicillin, ethyl icosapentate, itraconazole, and oxatomi Do, olopatadine, dalibzole, darubithion, ketofeneruvuzon, cobamamide, cisapride, todralazine, tropisetron, domperidone, valproic acid, pyridoxal, fluorouracil, flunarizine, flurazepam, benidipine, minocycline, mebenzoline
- active ingredients selected from the group consisting of roxyprogesterone, ubide force renone, lepodova and salts thereof.
- the active ingredient is contained in an amount of about 0.01 to 90 parts by weight in one tablet (the weight of one tablet is 100 parts by weight).
- the dividable tablet of the present invention is preferably used as a pharmaceutical, but is also preferably used for foods, cosmetics, agricultural chemicals, veterinary drugs, and the like.
- the divided tablet of the present invention may contain various additives used in the production of general preparations, and the added amount may be the amount used in the production of general preparations.
- additives include excipients, binders, disintegrants, lubricants, flavoring agents, foaming agents, sweeteners, flavors, coloring agents, stabilizers, and solubilizers.
- excipients examples include sugars such as lactose, mannitol, sucrose and glucose; starches such as potato starch, corn starch and partially pregelatinized starch; inorganic salts such as precipitated calcium carbonate, calcium phosphate and sodium chloride; Alternatively, crystalline cellulose and the like can be mentioned, and other known materials can be used without any limitation. Excipients are generally included in the range of about 10 parts by weight to 98 parts by weight during the disintegration (the weight of one tablet is 100 parts by weight).
- the binder include partially saponified polyvinyl alcohol, hydroxyprocellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, pullulan, methylcellulose, gum arabic and starches. It can be used without. The binder is generally contained in an amount of about 0.5 to 15 parts by weight in one tablet (the weight of one tablet is 100 parts by weight).
- disintegrant examples include crospovidone, low-substituted hydroxypropyl Cellulose, croscarmellose sodium, carboxymethylcellulose, carboxymethylcellulose calcium, carboxymethyl starch sodium, partially pregelatinized starch hydroxypropyl starch, corn starch, potato starch, crystalline cellulose or powdered cellulose, etc.
- any known materials can be used without any limitation.
- the disintegrant is generally contained in an amount of about 1 part by weight to 30 parts by weight in one tablet (the weight of one tablet is 100 parts by weight).
- the lubricating tablets include magnesium stearate, calcium stearate, zinc stearate, stearic acid, talc, hydrogenated vegetable oil and talc, and preferably magnesium stearate or calcium stearate.
- the lubricant is generally contained in an amount of about 0.01 to 5 parts by weight per tablet (the weight of one tablet is 100 parts by weight).
- flavoring agent examples include organic acid salts for flavoring such as sodium glutamate, sodium 5'-inonate, sodium 5'-guanylate, sodium aspartate, and the like. It can be used without any restrictions.
- foaming agent examples include baking soda, sodium carbonate, and the like. Any other known foaming agent can be used without any limitation.
- sweetener examples include aspartame, sodium saccharin, stevia, and the like. Any other known sweetener can be used without any limitation.
- flavor examples include lemon, orange, and menthol, and any other known ingredients can be used without any limitation.
- colorant examples include food colors such as Food Yellow No. 5, Food Red No. 2 and Food Blue No. 2, edible lake dyes, iron oxide, and the like. Can be used without any restrictions.
- stabilizer examples include sodium edetate, tocopherol, cyclodextrin and the like, and any other known stabilizers can be used without any limitation.
- solubilizer examples include polyethylene glycol, cyclodextrins, hydroxypropylcyclodextrins, and polyvinylpyrrolidone (PVP). Any other known ones can be used without any limitation. .
- the use or administration method of the divided tablet in the present invention is not particularly limited.
- the divided tablet in the present invention may be any of an oral tablet, an effervescent tablet, a dispensing tablet, a chewable tablet, a rapidly disintegrating tablet in the oral cavity, a troche or an oral tablet such as a buccal or sublingual tablet.
- the divided tablet in the present invention may be a functional tablet such as a multiple unit tablet, a gradumet, a wax matrix, a resinate or a spanner, in addition to the ordinary tablet and the coating tablet.
- the active ingredient and various additives are prepared by, for example, fluidized bed granulation, stirring granulation, tumbling granulation, tumbling fluidized bed granulation, and extrusion granulation.
- the mixture is granulated with a lubricant, if desired, to give a tableting powder, which is then compressed using a tableting machine known per se, preferably a one-shot tableting machine or a single-shot tableting machine with excellent productivity.
- a tableting machine known per se preferably a one-shot tableting machine or a single-shot tableting machine with excellent productivity.
- An indirect tableting method in which a tablet is locked can be used.
- a mixture of the active ingredient and various additives is used as a tableting powder, and is directly tableted by a known tableting machine, preferably a tableting machine or a single-shot tableting machine with excellent productivity.
- a tableting method is also included.
- a lubricant is applied to a punch and die of a tableting machine at the time of compression molding, and then compression-molded. You can also.
- the divided tablet of the present invention can be film-coated if desired. Coatings applied to tablets of the present invention are those commonly used for coating tablets. Is fine.
- An example of a film-forming polymer that can be used to form a film coating is a cellulose polymer.
- the cellulose polymer preferably has a molecular weight of 7500 to 120,000 and a viscosity of 1.5 to 2 OmmVs (25 ° C).
- the cell-mouth monoether-based polymer which is one of the cellulose polymers, includes hydroxypropyl methylcellulose (HPMC;), hydroxypropyl cellulose, methylcellulose, ethylcellulose, and the like.
- HPMC hydroxypropyl methylcellulose
- TC-15 hydroxypropyl methylcellulose 2910, Japanese Pharmacopoeia
- the dividing method of the divided tablet of the present invention is not particularly limited.
- the tablet can be easily divided by sandwiching and holding the divided tablet of the present invention between two flat plates.
- the dividing can be performed by pressing a finger or the like with the dividing line facing downward on a flat surface.
- the division can be performed by pressing the finger with a finger or the like with the dividing line facing upward on a flat surface.
- the split tablet of the present invention can be split by the above method.
- the split tablet of the present invention can be obtained by grasping the tablet with both hands to open (or close) the score line, or on a hard flat surface such as a desk, along or along the score line with an edge of a spoon or the like. It can also be divided by a method such as pressing the back side.
- the present invention will be described specifically with reference to Examples, but these Examples are not intended to limit the present invention.
- Lactose (manufactured by DMV: 200M) 66.6% by weight, corn starch (manufactured by Japan Food Processing Co., Ltd .: Eclipse Corn Starch W) 29.4% by weight, fluidized bed granulator (Freund: Floco Ichiichi FL-1) 15) Charged in, partially saponified poly as binder A 10% by weight aqueous solution of vinyl alcohol (manufactured by Nippon Gosei: Gosenol EG-05) was prepared, sprayed on the above mixture, granulated, and dried to obtain a dry powder. Obtained. The dry powder contained 3% by weight of a binder.
- the dried powder prepared as described above is sized using a sizing machine (manufactured by Tokuju Kosakusho: Landel Mill RM-I), and the obtained sized product is lubricated with magnesium stearate (manufactured by Sakai Kagaku Co., Ltd.). ) was added to the mixture in an amount of 1% by weight, and the mixture was mixed for 5 minutes by a blender (manufactured by Tokuju Kousakusho: Mix-Pell Mixer VI-60) to obtain a molding material.
- a sizing machine manufactured by Tokuju Kosakusho: Landel Mill RM-I
- magnesium stearate manufactured by Sakai Kagaku Co., Ltd.
- the sensory test in the table means that five panelists randomly selected have a flat table on which a dividing line is faced down and pressed with a finger to divide them. Easy to break: 3 points, Slightly hard to break: 2 points, Hard to break: 1 point, Not crackable: 0 points), with a score of 15 out of 15 points ⁇ , 10-1 4 points were evaluated as ⁇ , 5 to 9 points as ⁇ , and 4 or less as X.
- the evaluation of ⁇ which answered that most of the panelists were easy to crack, is preferable, and the evaluation of ⁇ , which all the panelists answered that they are easily broken, is extremely preferable.
- the CV () after splitting in the table is the percentage of the weight of 20 half-tablets obtained by dividing 10 tablets and dividing the standard deviation by the average value. It indicates that the division was performed correctly, and the value is preferably 2 to 4, and very preferably 2 or less. Table 1
- the tablet when the tablet was divided by pressing the finger with the score line downward on a flat surface, the tablet could be easily and accurately divided in any case.
- the ratio of c and d is cZd, where 1 ⁇ 0.60 ⁇ c // d ⁇ 1 / 0.40, and b is 75 ° or more and less than 78 °
- the ratio c / d is 1Z0.65 ⁇ c / d ⁇ 1 / 0.40
- the b force is 78 ° or more
- the ratio of c and d is cZd force 1 /
- 0.70 ⁇ c / d ⁇ 1 / 0.40 it was possible to split more easily and accurately.
- the tablet can be divided by sandwiching and holding the divided tablet between two flat plates, and can also be divided by pressing the dividing line downward on a flat surface and pressing it with a finger or the like.
- the tablet can be divided in the same manner even from the top of the packaging of PTP, etc., and preferably the tablet can be divided with either the upper or lower surface facing upward, and can be divided easily and accurately.
- a divided tablet having further excellent strength can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Packages (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004226542A AU2004226542A1 (en) | 2003-03-28 | 2004-03-26 | Scored tablet |
CA002520562A CA2520562A1 (en) | 2003-03-28 | 2004-03-26 | Dividable tablet |
JP2005504214A JPWO2004087110A1 (ja) | 2003-03-28 | 2004-03-26 | 分割錠 |
US10/548,579 US20060228409A1 (en) | 2003-03-28 | 2004-03-26 | Scored tablet |
EP04723771A EP1627630A1 (en) | 2003-03-28 | 2004-03-26 | Dividable tablet |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003092745 | 2003-03-28 | ||
JP2003-092745 | 2003-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004087110A1 true WO2004087110A1 (ja) | 2004-10-14 |
Family
ID=33127337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/004369 WO2004087110A1 (ja) | 2003-03-28 | 2004-03-26 | 分割錠 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060228409A1 (ja) |
EP (1) | EP1627630A1 (ja) |
JP (1) | JPWO2004087110A1 (ja) |
KR (1) | KR20050121701A (ja) |
CN (1) | CN1767816A (ja) |
AU (1) | AU2004226542A1 (ja) |
CA (1) | CA2520562A1 (ja) |
TW (1) | TW200502000A (ja) |
WO (1) | WO2004087110A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007326835A (ja) * | 2006-06-09 | 2007-12-20 | Takada Seiyaku Kk | 分割錠剤 |
JP2008208078A (ja) * | 2007-02-27 | 2008-09-11 | Takada Seiyaku Kk | 分割錠剤 |
JP2012036159A (ja) * | 2010-08-11 | 2012-02-23 | Dainippon Sumitomo Pharma Co Ltd | 分割可能な錠剤 |
JP5509086B2 (ja) * | 2008-09-16 | 2014-06-04 | 武田薬品工業株式会社 | フィルムコーティング割線錠剤 |
JP2018030896A (ja) * | 2014-02-07 | 2018-03-01 | サイラブス, ファーマシューティカルズ | 全自然非毒性舌下薬剤の送達システム |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007104583A1 (en) * | 2006-03-16 | 2007-09-20 | Berlin-Chemie Ag | Accurately divisible tablet |
TR200708925A1 (tr) * | 2007-12-26 | 2009-07-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Kontrollü salım sağlayan flurbiprofen ve kas gevşetici kombinasyonları |
WO2010022385A2 (en) * | 2008-08-22 | 2010-02-25 | United States Pharmaceutical Distributors, Inc. | Container for use in pneumatic transport system |
CA2954086C (en) | 2014-07-11 | 2020-03-31 | Azanta Danmark A/S | Misoprostol dispersible tablet |
FR3066694B1 (fr) * | 2017-05-23 | 2020-02-21 | Ceva Sante Animale | Comprime secable |
CN112823639A (zh) * | 2019-11-20 | 2021-05-21 | 李国龙 | 食品结构及其制造方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS403680Y1 (ja) * | 1964-09-24 | 1965-02-01 | ||
GB1387643A (en) * | 1971-03-16 | 1975-03-19 | Ives Lab Inc | Divisible tablet |
JPS55162714A (en) * | 1979-03-26 | 1980-12-18 | Bristol Myers Co | Tablet structure |
JPS61289027A (ja) * | 1985-06-04 | 1986-12-19 | サンド・アクチエンゲゼルシヤフト | 錠剤 |
JPH0853345A (ja) * | 1994-08-10 | 1996-02-27 | Pfizer Pharmaceut Co Ltd | フィルムコーティングを施した分割錠剤 |
JPH08277218A (ja) * | 1995-04-04 | 1996-10-22 | Kyowa Hakko Kogyo Co Ltd | 割溝付き錠剤および割溝形成凸部付き杵 |
WO1999018008A1 (fr) * | 1997-10-02 | 1999-04-15 | Kyowa Hakko Kogyo Co., Ltd. | Emballage a expulsion par pression, feuille de scellage pour ledit emballage et procede d'elaboration de comprimes |
WO1999051207A1 (fr) * | 1998-04-03 | 1999-10-14 | Kyowa Hakko Kogyo Co., Ltd. | Comprime secable et conditionnement au travers duquel appliquer une force de pression |
JP2002028222A (ja) * | 2000-04-28 | 2002-01-29 | Kyowa Hakko Kogyo Co Ltd | 錠剤分割器具、錠剤及びプレススルーパック |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4258027A (en) * | 1979-03-26 | 1981-03-24 | Mead Johnson & Company | Multi-fractionable tablet structure |
US4353887A (en) * | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
US4824677A (en) * | 1986-12-18 | 1989-04-25 | The Unjohn Company | Grooved tablet for fractional dosing of sustained release medication |
-
2004
- 2004-03-12 TW TW093106602A patent/TW200502000A/zh unknown
- 2004-03-26 CN CNA200480008588XA patent/CN1767816A/zh active Pending
- 2004-03-26 KR KR1020057018324A patent/KR20050121701A/ko not_active Withdrawn
- 2004-03-26 WO PCT/JP2004/004369 patent/WO2004087110A1/ja not_active Application Discontinuation
- 2004-03-26 JP JP2005504214A patent/JPWO2004087110A1/ja active Pending
- 2004-03-26 EP EP04723771A patent/EP1627630A1/en not_active Withdrawn
- 2004-03-26 CA CA002520562A patent/CA2520562A1/en not_active Abandoned
- 2004-03-26 US US10/548,579 patent/US20060228409A1/en not_active Abandoned
- 2004-03-26 AU AU2004226542A patent/AU2004226542A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS403680Y1 (ja) * | 1964-09-24 | 1965-02-01 | ||
GB1387643A (en) * | 1971-03-16 | 1975-03-19 | Ives Lab Inc | Divisible tablet |
JPS55162714A (en) * | 1979-03-26 | 1980-12-18 | Bristol Myers Co | Tablet structure |
JPS61289027A (ja) * | 1985-06-04 | 1986-12-19 | サンド・アクチエンゲゼルシヤフト | 錠剤 |
JPH0853345A (ja) * | 1994-08-10 | 1996-02-27 | Pfizer Pharmaceut Co Ltd | フィルムコーティングを施した分割錠剤 |
JPH08277218A (ja) * | 1995-04-04 | 1996-10-22 | Kyowa Hakko Kogyo Co Ltd | 割溝付き錠剤および割溝形成凸部付き杵 |
WO1999018008A1 (fr) * | 1997-10-02 | 1999-04-15 | Kyowa Hakko Kogyo Co., Ltd. | Emballage a expulsion par pression, feuille de scellage pour ledit emballage et procede d'elaboration de comprimes |
WO1999051207A1 (fr) * | 1998-04-03 | 1999-10-14 | Kyowa Hakko Kogyo Co., Ltd. | Comprime secable et conditionnement au travers duquel appliquer une force de pression |
JP2002028222A (ja) * | 2000-04-28 | 2002-01-29 | Kyowa Hakko Kogyo Co Ltd | 錠剤分割器具、錠剤及びプレススルーパック |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007326835A (ja) * | 2006-06-09 | 2007-12-20 | Takada Seiyaku Kk | 分割錠剤 |
JP2008208078A (ja) * | 2007-02-27 | 2008-09-11 | Takada Seiyaku Kk | 分割錠剤 |
JP5509086B2 (ja) * | 2008-09-16 | 2014-06-04 | 武田薬品工業株式会社 | フィルムコーティング割線錠剤 |
JP2012036159A (ja) * | 2010-08-11 | 2012-02-23 | Dainippon Sumitomo Pharma Co Ltd | 分割可能な錠剤 |
JP2018030896A (ja) * | 2014-02-07 | 2018-03-01 | サイラブス, ファーマシューティカルズ | 全自然非毒性舌下薬剤の送達システム |
Also Published As
Publication number | Publication date |
---|---|
KR20050121701A (ko) | 2005-12-27 |
US20060228409A1 (en) | 2006-10-12 |
AU2004226542A1 (en) | 2004-10-14 |
CA2520562A1 (en) | 2004-10-14 |
JPWO2004087110A1 (ja) | 2006-06-29 |
TW200502000A (en) | 2005-01-16 |
EP1627630A1 (en) | 2006-02-22 |
CN1767816A (zh) | 2006-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5219092B2 (ja) | 分割容易な錠剤および分割容易な錠剤の製造方法 | |
JP2848966B2 (ja) | 分割可能な錠剤の製造方法 | |
RU2493830C2 (ru) | Лекарственная форма | |
AU2005245027B2 (en) | Pharmaceutical tablets having a separation mark positioned on the side of said tablets | |
WO2004087110A1 (ja) | 分割錠 | |
EP3130334B1 (en) | Controlled-release solid preparation with partial coating | |
TW200940109A (en) | Dividable galenical form allowing modified release of the active ingredient | |
JP2008208078A (ja) | 分割錠剤 | |
JPS61289027A (ja) | 錠剤 | |
JP3015677B2 (ja) | フィルムコーティングを施した分割錠剤 | |
JP4341690B2 (ja) | 割線錠剤 | |
JP5719479B1 (ja) | 容易な分割性を有する錠剤 | |
JP2006231079A (ja) | 錠剤の分割方法、分割容易化方法および分割容易な錠剤の製造方法 | |
JP5049517B2 (ja) | 分割錠剤 | |
TW202015661A (zh) | 薄型錠劑、薄型錠劑製造方法及薄型錠劑製造裝置 | |
KR101422052B1 (ko) | 할선 정제 | |
JP2006052230A (ja) | 分割錠剤及びプレススルーパック | |
JP6177720B2 (ja) | 容易な服用性と分割性を有する錠剤 | |
WO2015087561A1 (ja) | 容易な分割性を有する錠剤 | |
RENUKA | INTERNATIONAL JOURNAL OF INVENTIONS IN PHARMACEUTICAL SCIENCES | |
JP2018127431A (ja) | 固形医薬製剤及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004226542 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005504214 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004723771 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2520562 Country of ref document: CA Ref document number: 2420/CHENP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057018324 Country of ref document: KR Ref document number: 2004808588X Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2004226542 Country of ref document: AU Date of ref document: 20040326 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004226542 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006228409 Country of ref document: US Ref document number: 10548579 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057018324 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004723771 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10548579 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004723771 Country of ref document: EP |